CPC A61K 49/0428 (2013.01) [A61K 31/12 (2013.01); A61K 47/6803 (2017.08); A61K 47/6883 (2017.08); A61K 47/6923 (2017.08); A61K 47/6929 (2017.08); A61K 49/08 (2013.01); A61K 49/1878 (2013.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01)] | 9 Claims |
1. A chemotherapeutic drug carrier composition, comprising:
a platform of nanoporous structured silica in the form of a mesocellular foam superparamagnetic iron oxide nanoparticles (“SPIONS”) in an amount in a range of from 5 wt % to 20 wt % based on total weight of the composition, and
a curcuminoid loaded in a range of from 50 to 70 wt. %,
wherein the SPIONs have an average particle size in a range of from 13 to 58 nm,
wherein the platform loaded with the SPIONs has a BET surface area in a range of from 140 to 951 m2/g,
wherein the SPIONs comprise Fe2O3 or a mixture of NiFe2O4, CuFe2O4, MnFe2O4, or CoFe2O4, and
wherein the composition has a non-burst release profile with a cumulative curcuminoid release, in phosphate buffered saline at pH 5 and 37° C. over 3 hours, in a range of from 21.3 to 53.2 wt. %, relative to total curcuminoid content in the composition.
|